In recent trading, shares of Genmab A/S (Symbol: GMAB) have crossed above the average analyst 12-month target price of $43.85, changing hands for $44.69/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.